Overview: Diphtheria Pertussis Tetanus IgG Antibody Panel
Introduction: The Diphtheria Pertussis Tetanus IgG Antibody Panel is a diagnostic tool designed to assess vaccine response using serum samples. In India, DPT vaccination coverage is ~90 percent nationally but lower in rural areas, with waning immunity leading to diphtheria outbreaks (sporadic cases), pertussis resurgence, and tetanus in neonates/unvaccinated adults. IgG levels indicate protective immunity post-vaccination or natural exposure. High morbidity from under-testing in outbreak settings or high-risk groups (neonates, pregnant women), limited serology access, delayed booster administration. Per microbiology practices aligned with ICMR, UIP, and IDSP guidelines, the test employs immunoassay for diphtheria, pertussis, and tetanus IgG over 1-2 days with high specificity, valuable for evaluating vaccine efficacy and guiding boosters. This diagnostic falls under immunity screening and targets vaccinated individuals, outbreak contacts, or pregnant women, addressing accurate detection to inform revaccination. With elevated morbidity due to waning immunity, the test supports public health efforts by enabling precise immunity assessment and reducing vaccine-preventable disease burden. Its serum-based approach ensures reliable detection.
Other Names: DPT IgG Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Serologic vaccine response testing; in India, used in outbreak investigations.
Purpose: The test screens for 3 parameters including diphtheria IgG to guide vaccine response assessment, detect protective immunity, inform booster needs.
Test Parameters: 1. Diphtheria IgG, 2. Pertussis IgG, 3. Tetanus IgG.
Pretest Condition: No fasting required; patients should report vaccination history or exposure.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on vaccination doses, dates, recent exposure, symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of low immunity including disease susceptibility, benefits of assessment, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or immunosuppression can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Protective IgG levels indicate immunity; low levels suggest need for booster, necessitating specialist input.
Specialist Consultation: Pediatricians or infectious disease specialists should be consulted for management.
Additional Supporting Tests: Toxin neutralization for confirmation.
Test Limitations: IgG levels vary with time post-vaccination; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, Vaccine Studies India 2023.
